Cell Therapy Market is expected to reach US$ 12,563.23 million in 2027

Allogeneic Segment to Grow at Faster CAGR During 2020–2027

According to our new research study Cell Therapy Market Forecast To 2027 - Global Analysis by Product Type, Technology, Application, End-user” the cell therapy market size is expected to reach US$ 12,563.23 million in 2027 from US$ 7,260.50 million in 2019; it is estimated to grow at a CAGR of 7.2% from 2020 to 2027.

The report highlights trends prevailing in the market, and the factors driving and hindering the cell therapy market growth. The growth of the cell therapy market is due to the rising increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and increasing number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the cell therapy market growth during the forecast period.

Global Cell Therapy Market, by Region, 2019 (%)

Based on therapy type, the global cell therapy market is segmented into allogeneic, and autologous. The allogeneic segment is likely to hold the largest share of the cell therapy market in 2019. However, the autologous segment is anticipated to register the highest CAGR in the cell therapy market during the forecast period. Allogeneic therapies are made beforehand in large numbers and are used to treat many patients. As these are produced in large numbers, require following Good Manufacturing Practice (GMP), and hence products produced are quality controlled. Manufacturers are focusing on the development of regenerative therapies by increasingly emphasizing innovations. Many of the regenerative therapeutic applications have gained approval for clinical trials in the US, Europe, and the Asia Pacific due to the effectiveness of allogeneic stem cell therapeutics. This approvals for clinical trials are helping market players to launch new product lines to accelerate the overall product demand for stem therapy using allogeneic stem cell therapeutics. For instance, in 2023, The FDA approved Gamida Cell’s stem cell transplant (SCT) therapy Omisirge for treating blood cancer patients undergoing SCT. This therapy represents the first allogeneic cell therapy product indicated for SCT approved by the FDA. It is set to address a real unmet need for patients unable to find a matched donor. Thus, above mentioned factors are expected to drive cell therapy market growth during the forecast period. Therefore, the growth of the cell therapy market is primarily driven by the above-mentioned factors.    

Vericel Corporation, MEDIPOST, NuVasive, Inc., Mesoblast Limited, JCR Pharmaceuticals Co. Ltd., Smith & Nephew, Bristol-Myers Squibb Company, Cells for Cells, Stemedica Cell Technologies, Inc, and Castle Creek Biosciences, Inc. among others are the leading companies operating in the global cell therapy market.

The report segments the cell therapy market as follows:

Based on the therapy type, the cell therapy market is categorized into allogeneic, and autologous. Based on product, the cell therapy market is segmented into consumables, equipment, systems and software. Based on technology, the cell therapy market is segmented into viral vector technology, genome editing technology, somatic cell technology, cell immortalization technology, cell plasticity technology, and three-dimensional technology. Based on geography, the cell therapy market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com